Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab

Filing Before Pivotal Data Beats Lilly’s Pre-Phase III Submission

 
• By Mandy Jackson
  
Pair of aces with poker chips
Time will tell if Eisai and Biogen are holding a pair of aces with Aduhelm and lecanemab • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category